Technical Analysis for BIOC - Biocept, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Historical BIOC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -3.61% | |
| Outside Day | Range Expansion | -3.61% | |
| Wide Bands | Range Expansion | -3.61% | |
| Oversold Stochastic | Weakness | -3.61% | |
| Wide Bands | Range Expansion | -8.08% | |
| Oversold Stochastic | Weakness | -8.08% | |
| 200 DMA Support | Bullish | -1.53% | |
| 50 DMA Support | Bullish | -1.53% | |
| Stochastic Reached Oversold | Weakness | -1.53% | |
| Wide Bands | Range Expansion | -1.53% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 50 DMA Support | about 2 hours ago | |
| Down 5% | about 2 hours ago | |
| 60 Minute Opening Range Breakdown | about 2 hours ago | |
| Down 3% | about 2 hours ago | |
| Down 2 % | about 2 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/23/2021
Biocept, Inc., a cancer diagnostics company, is engaged in the development and commercialization of proprietary circulating tumor cell (CTC) and circulating tumor DNA tests. The company's tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. Its tests include OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company sells its products through its sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Oncology Breast Cancer Treatment Of Breast Cancer Tumor Tumors Anatomical Pathology Cancer Center Tumor Cell Foundation Medicine
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Clinical Medicine Oncology Breast Cancer Treatment Of Breast Cancer Tumor Tumors Anatomical Pathology Cancer Center Tumor Cell Foundation Medicine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.0 |
| 52 Week Low | 2.112 |
| Average Volume | 550,126 |
| 200-Day Moving Average | 5.83 |
| 50-Day Moving Average | 5.99 |
| 20-Day Moving Average | 6.91 |
| 10-Day Moving Average | 6.72 |
| Average True Range | 0.61 |
| ADX | 28.2 |
| +DI | 24.17 |
| -DI | 24.97 |
| Chandelier Exit (Long, 3 ATRs ) | 6.54 |
| Chandelier Exit (Short, 3 ATRs ) | 7.48 |
| Upper Bollinger Band | 8.02 |
| Lower Bollinger Band | 5.79 |
| Percent B (%b) | 0.17 |
| BandWidth | 32.30 |
| MACD Line | 0.07 |
| MACD Signal Line | 0.26 |
| MACD Histogram | -0.1909 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.56 | ||||
| Resistance 3 (R3) | 7.68 | 7.33 | 7.32 | ||
| Resistance 2 (R2) | 7.33 | 6.98 | 7.27 | 7.24 | |
| Resistance 1 (R1) | 6.75 | 6.76 | 6.58 | 6.63 | 7.17 |
| Pivot Point | 6.40 | 6.40 | 6.32 | 6.34 | 6.40 |
| Support 1 (S1) | 5.82 | 6.05 | 5.65 | 5.70 | 5.15 |
| Support 2 (S2) | 5.47 | 5.83 | 5.41 | 5.08 | |
| Support 3 (S3) | 4.89 | 5.47 | 5.00 | ||
| Support 4 (S4) | 4.77 |
